坎地沙坦与安慰剂预防发作性偏头痛:随机三盲安慰剂对照2期试验
这项在挪威和爱沙尼亚多中心开展的随机三盲安慰剂对照2期试验,将457例每月2–8次发作的发作性偏头痛成人分配至坎地沙坦16 mg、8 mg或安慰剂组治疗12周。最常见不良事件为头晕(16 mg组30% vs 安慰剂组13%)。
要点
- 坎地沙坦16 mg每日一次可有效减少发作性偏头痛天数。
- 头晕是最常见不良事件,16 mg组发生率为30%。
核心结论
- 每日坎地沙坦16 mg对发作性偏头痛预防有效且耐受良好,支持其作为有临床意义且循证的选择。
研究设计与样本
- 随机、三盲、安慰剂对照、平行组2期试验,在挪威9家医院和爱沙尼亚1家大型医院开展。
- 457例18–64岁、每月2–8次偏头痛发作(伴或不伴先兆)的成人按1:1:1随机接受口服坎地沙坦16 mg、8 mg或安慰剂每日一次共12周。
- 主要终点为基线至第9–12周每4周平均偏头痛天数变化,在意向治疗人群中分析。
主要发现
- 坎地沙坦16 mg组头晕报告46/156例(30%),安慰剂组19/151例(13%)。
- 严重不良事件在坎地沙坦16 mg组报告4/156例(3%),安慰剂组1/151例(1%)。
- 因不良事件停药在坎地沙坦16 mg组和安慰剂组均为4例(3%)。
临床怎么用
- 对于发作性偏头痛成人,可考虑每日坎地沙坦16 mg作为预防治疗选项。
- 用药时需关注头晕等不良事件,严重不良事件少见。
- 长期疗效仍需进一步临床试验和注册研究真实世界数据评估。
局限性
- 原文未报告8 mg组的主要终点结果。
- 长期疗效尚需进一步临床试验和注册研究真实世界数据评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Effective and well-tolerated preventive treatments for migraine remain few, and the angiotensin receptor blocker candesartan has shown promise in small studies. This study aimed to evaluate the safety, tolerability, and efficacy of candesartan for the preventive treatment of episodic migraine. METHODS: This randomised, triple-blind, placebo-controlled, parallel-group, phase 2 trial was done at nine hospitals across Norway and one large hospital in Estonia, selected for their neurological services and research capacity. Adults aged 18-64 years, experiencing between two and eight migraine attacks (with or without aura) per month were randomly assigned (1:1:1) to receive oral candesartan 16 mg, candesartan 8 mg, or placebo daily for 12 weeks. Acute migraine medication was permitted during the trial but the use of other preventive treatments were prohibited. Participants, site personnel, and the trial statistician were all masked to treatment allocation. The primary endpoint was the change in the mean number of migraine days per 4 weeks from baseline to weeks 9-12, analysed in the intention-to-treat population (participants with at least one post-baseline measurement during the masked treatment period). Safety analyses included all participants who received at least one dose of the trial drug. This trial is registered with ClinicalTrials.gov (NCT04574713; Oct 5, 2020) and is completed. FINDINGS: Between April 9, 2021, and April 12, 2024, 1340 individuals were assessed for eligibility, 806 were deemed ineligible, and 534 were enrolled in the trial. Of these, 77 were excluded, and 457 participants were randomly assigned to candesartan 16 mg (n=156), candesartan 8 mg (n=150), or placebo (n=151). The mean age of the trial population was 38·7 years (SD 10·0); 391 (86%) participants were female and 66 (14%) were male. The mean number of migraine days was 5·7 (SD 2·5) at baseline. By weeks 9-12, the reduction in migraine days was 2·04 days (95% CI 1·65-2·41 p<0·0001) in the candesartan 16 mg group compared with 0·82 days (0·38-1·23; p=0·0003) in the placebo group ((difference between groups -1·22 [95% CI -1·75 to -0·70]; p<0·0001). The most common adverse event with candesartan 16 mg was dizziness, reported in 46 (30%) of 156 participants, compared with 19 (13%) of 151 in the placebo group. Serious adverse events were reported in four (3%) participants in the candesartan 16 mg group and one (1%) participant in the placebo group. Adverse events leading to discontinuation occurred in four (3%) participants in both the candesartan 16 mg and placebo groups. INTERPRETATION: Daily administration of candesartan 16 mg is effective and well tolerated as a preventive treatment for episodic migraine. These findings support its role as a clinically meaningful and evidence-based option for migraine prevention. However, further clinical trials and real-world data from registry studies are necessary to assess its long-term efficacy. FUNDING: Norwegian Research Council.
引用
- Øie LR, Wergeland T, Salvesen Ø, et al. Candesartan versus placebo for migraine prevention in patients with episodic migraine: a randomised, triple-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2025. PMID: 40975098. doi:10.1016/S1474-4422(25)00269-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。